Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.

Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, Ängeby K, Jureen P, Moradigaravand D, Parkhill J, Peacock SJ, Schön T, Maurer FP, Walker T, Köser C, Niemann S.

Genome Med. 2020 Mar 6;12(1):27. doi: 10.1186/s13073-020-00726-5.

2.

Network Experiences from a Cross-Sector Biosafety Level-3 Laboratory Collaboration: A Swedish Forum for Biopreparedness Diagnostics.

Thelaus J, Lindberg A, Thisted Lambertz S, Byström M, Forsman M, Lindmark H, Knutsson R, Båverud V, Bråve A, Jureen P, Lundin Zumpe A, Melefors Ö.

Health Secur. 2017 Jul/Aug;15(4):384-391. doi: 10.1089/hs.2016.0082. Epub 2017 Aug 14.

3.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

4.

Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats.

Nisii C, Grunow R, Brave A, Ippolito G, Jacob D, Jureen P, Bartolini B, Di Caro A; EMERGE Viral Pathogens Working Group.

Adv Exp Med Biol. 2017;972:123-129. doi: 10.1007/5584_2016_152.

PMID:
28032326
5.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

6.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
7.

Detection of Drug-Resistant Mycobacterium tuberculosis.

Engström A, Juréen P.

Methods Mol Biol. 2015;1315:349-62. doi: 10.1007/978-1-4939-2715-9_24.

PMID:
26103910
8.

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

9.

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T.

Clin Microbiol Infect. 2015 Feb;21(2):148.e5-7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29.

10.

Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Schön T, Simonsson US, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K.

Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22.

11.

A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability.

Larsson MC, Lerm M, Ängeby K, Nordvall M, Juréen P, Schön T.

J Microbiol Methods. 2014 Nov;106:146-150. doi: 10.1016/j.mimet.2014.08.015. Epub 2014 Sep 3.

PMID:
25194234
12.

Multidrug-resistant Myobacterium tuberculosis caused by the Beijing genotype and a specific T1 genotype clone (SIT No. 266) is widely transmitted in Minsk.

Zalutskaya A, Wijkander M, Jureen P, Skrahina A, Hoffner S.

Int J Mycobacteriol. 2013 Dec;2(4):194-8. doi: 10.1016/j.ijmyco.2013.08.001. Epub 2013 Sep 6.

13.

Detection of heteroresistant Mycobacterium tuberculosis by pyrosequencing.

Engström A, Hoffner S, Juréen P.

J Clin Microbiol. 2013 Dec;51(12):4210-2. doi: 10.1128/JCM.01761-13. Epub 2013 Sep 18.

14.

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

Schön T, Juréen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Angeby K.

J Antimicrob Chemother. 2013 Sep;68(9):2074-7. doi: 10.1093/jac/dkt150. Epub 2013 Apr 30.

PMID:
23633684
15.

Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.

Ängeby K, Juréen P, Chryssanthou E, Schön T.

Int J Mycobacteriol. 2012 Dec;1(4):177-9. doi: 10.1016/j.ijmyco.2012.09.002. Epub 2012 Oct 11.

16.

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T.

Bull World Health Organ. 2012 Sep 1;90(9):693-8. doi: 10.2471/BLT.11.096644. Epub 2012 May 29.

17.

Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.

Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia L, Merza MA, Muntean I, Bwanga F, Joloba M, Hoffner SE.

Int J Mycobacteriol. 2012 Sep;1(3):124-30. doi: 10.1016/j.ijmyco.2012.08.001. Epub 2012 Aug 31.

18.

Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.

Engström A, Morcillo N, Imperiale B, Hoffner SE, Juréen P.

J Clin Microbiol. 2012 Jun;50(6):2026-33. doi: 10.1128/JCM.06664-11. Epub 2012 Mar 29.

19.

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1253-7. doi: 10.1128/AAC.05894-11. Epub 2011 Dec 27.

20.

Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.

Angeby K, Giske CG, Juréen P, Schön T, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2011 Sep;55(9):4492-3; author reply 4493. doi: 10.1128/AAC.00232-11. No abstract available.

21.

Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.

Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P.

J Antimicrob Chemother. 2011 Jun;66(6):1247-54. doi: 10.1093/jac/dkr109. Epub 2011 Mar 21.

PMID:
21427106
22.

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

Schön T, Juréen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G, Hoffner S, Angeby KA.

Int J Tuberc Lung Dis. 2011 Apr;15(4):502-9. doi: 10.5588/ijtld.10.0238.

PMID:
21396210
23.

Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.

Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, Juréen P, Hoffner S, Del Portillo P, Morcillo N, Palomino JC.

J Antimicrob Chemother. 2011 Apr;66(4):827-33. doi: 10.1093/jac/dkq527. Epub 2011 Jan 19.

PMID:
21393176
24.

Rifampin-isoniazid oligonucleotide typing: an alternative format for rapid detection of multidrug-resistant Mycobacterium tuberculosis.

Hernández-Neuta I, Varela A, Martin A, von Groll A, Jureen P, López B, Imperiale B, Sķenders G, Ritacco V, Hoffner S, Morcillo N, Palomino JC, Del Portillo P.

J Clin Microbiol. 2010 Dec;48(12):4386-91. doi: 10.1128/JCM.00448-10. Epub 2010 Sep 29.

25.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23.

PMID:
20332195
26.

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T.

J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17.

27.

Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA.

Antimicrob Agents Chemother. 2009 Oct;53(10):4498-500. doi: 10.1128/AAC.00287-09. Epub 2009 Aug 17.

28.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.

PMID:
19633001
29.

Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Juréen P, Werngren J, Toro JC, Hoffner S.

Antimicrob Agents Chemother. 2008 May;52(5):1852-4. doi: 10.1128/AAC.00110-08. Epub 2008 Mar 3.

30.

Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.

Huitric E, Werngren J, Juréen P, Hoffner S.

Antimicrob Agents Chemother. 2006 Aug;50(8):2860-2.

31.

Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology.

Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE.

J Clin Microbiol. 2006 Jun;44(6):1925-9.

32.

Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.

Juréen P, Werngren J, Hoffner SE.

Tuberculosis (Edinb). 2004;84(5):311-6.

PMID:
15207806
33.

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.

Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S.

Antimicrob Agents Chemother. 2003 Sep;47(9):2971-3.

Supplemental Content

Loading ...
Support Center